Nuclear magnetic resonance-based metabolomic analysis in the assessment of preclinical atherosclerosis in type 1 diabetes and preeclampsia

Dr. Amor and collaborators have published a new article in the Diabetes Research and Clinical Practice journal using our plasma metabolomics analysis. The aim of the study was to evaluate the role of plasma metabolomics in atherosclerosis according to the presence of type 1 diabetes (T1D) or previous preeclampsia. They have concluded that plasma metabolomics […]

Metabolomics Reveals Reduction of Metabolic Oxidation in Women with Polycystic Ovary Syndrome after Pioglitazone-Flutamide-Metformin Polytherapy

Abstract Polycystic ovary syndrome (PCOS) is a variable disorder characterized by a broad spectrum of anomalies, including hyperandrogenemia, insulin resistance, dyslipidemia, body adiposity, low-grade inflammation and increased cardiovascular disease risks. Recently, a new polytherapy consisting of low-dose flutamide, metformin and pioglitazone in combination with an estro-progestagen resulted in the regulation of endocrine clinical markers in […]

From LAB to market

Last year we published 19 scientific articles in international journals. We are a metabolomics company halfway between research and clinical practice, a scientific research group in a business environment that is committed to translational research. We carry out scientific collaborations with research groups from universities, research institutions, hospitals and companies in the biomedical sector both […]

Predicting the future of health

Once infected by SARS-CoV-2, would you like to know your health status evolution?   This is Biosfer Teslab commitment in the SARS-CoV-2 pandemic. The Spanish Institute of Health Research Pere Virgili, Fundación Alcorcón University Hospital, SCIENCE&STRATEGY SL, Laboratorios Rubió SA, and Biosfer Teslab together with Treat systems (Denmark), Kinesys Consulting (UK), EuroCrime (Italy) have built […]